RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
IX Biopharma Stock

IX Biopharma P/E 2025

IX Biopharma P/E

2.41

Ticker

42C.SI

ISIN

SG1BD9000009

As of Feb 7, 2025, IX Biopharma's P/E ratio was 2.41, a -189.26% change from the -2.7 P/E ratio recorded in the previous year.

The IX Biopharma P/E history

IX Biopharma Aktienanalyse

What does IX Biopharma do?

IX Biopharma Ltd is a leading biopharmaceutical company based in Singapore. The company was founded in 2007 by Dr. Jan-Olof Heldin, a globally recognized biotech entrepreneur. The history of IX Biopharma dates back to the late 90s, when Dr. Heldin began working on a new method of drug delivery called "Oral Transmucosal Technology" (OTM). This technology allows for the development of drugs that can quickly and specifically penetrate the body, with a very high bioavailability. Today, IX Biopharma has a strong presence in the market for novel OTM-based drugs. The company operates in three different business areas: human medicine products, animal health, and life sciences. IX Biopharma's human medicine products are specialized in the treatment of pain and inflammation. The company has already launched a product - a fast-acting spray for pain relief. This new technology allows the medication to quickly enter the body and take effect, providing patients with rapid pain relief. IX Biopharma is currently working on additional products based on OTM technology to provide suitable solutions for other medical conditions as well. In the animal health sector, IX Biopharma offers veterinary products tailored to the needs of pets and livestock. The company collaborates closely with veterinarians and livestock experts to develop innovative therapies and treatment methods customized for specific animal needs. In the field of life sciences, IX Biopharma engages in a wide range of activities and services. These include the development of diagnostic products, conducting clinical trials, identifying biomarkers, and developing immunotherapies. Overall, IX Biopharma is an innovative biopharmaceutical company specializing in the development of drugs based on new technologies. The company is constantly striving to find innovative solutions to improve the health of humans and animals. With a dedicated team of scientists and researchers, as well as a strong presence in Asia and Europe, IX Biopharma is a pioneer in the new world of OTM-based drug development. IX Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering IX Biopharma's P/E Ratio

The Price to Earnings (P/E) Ratio of IX Biopharma is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing IX Biopharma's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of IX Biopharma is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in IX Biopharma’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about IX Biopharma stock

What is the price-to-earnings ratio of IX Biopharma?

The price-earnings ratio of IX Biopharma is currently 2.41.

How has the price-earnings ratio of IX Biopharma changed compared to last year?

The price-to-earnings ratio of IX Biopharma has increased by -189.26% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of IX Biopharma high compared to other companies?

Yes, the price-to-earnings ratio of IX Biopharma is high compared to other companies.

How does an increase in the price-earnings ratio of IX Biopharma affect the company?

An increase in the price-earnings ratio of IX Biopharma would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of IX Biopharma affect the company?

A decrease in the price-earnings ratio of IX Biopharma would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of IX Biopharma?

Some factors that influence the price-earnings ratio of IX Biopharma are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does IX Biopharma pay?

Over the past 12 months, IX Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, IX Biopharma is expected to pay a dividend of 0 SGD.

What is the dividend yield of IX Biopharma?

The current dividend yield of IX Biopharma is .

When does IX Biopharma pay dividends?

IX Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of IX Biopharma?

IX Biopharma paid dividends every year for the past 0 years.

What is the dividend of IX Biopharma?

For the upcoming 12 months, dividends amounting to 0 SGD are expected. This corresponds to a dividend yield of 0 %.

In which sector is IX Biopharma located?

IX Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von IX Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of IX Biopharma from 2/7/2025 amounting to 0 SGD, you needed to have the stock in your portfolio before the ex-date on 2/7/2025.

When did IX Biopharma pay the last dividend?

The last dividend was paid out on 2/7/2025.

What was the dividend of IX Biopharma in the year 2024?

In the year 2024, IX Biopharma distributed 0 SGD as dividends.

In which currency does IX Biopharma pay out the dividend?

The dividends of IX Biopharma are distributed in SGD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von IX Biopharma

Our stock analysis for IX Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of IX Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.